The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | 1L nivo + low dose ipi in pts with advanced gastric or esophago-gastric junction MSI-H tumors
Kei Muro, MD, PhD, Aichi Cancer Centre Hospital, Nagoya, Japan, discusses findings of a Phase II study investigating the efficacy and safety of first-line treatment with nivolumab plus low-dose ipilimumab in microsatellite instability-high (MSI-H) advanced gastric or esophagogastric junction cancer (GC). The chemo-free approach demonstrated high efficacy and good tolerability, supporting the use of this combination in MSI-H GC patients as a first-line therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
